Cite
1017TiP KEYNOTE-937 trial in progress: adjuvant pembrolizumab in patients with hepatocellular carcinoma (HCC) and complete radiologic response after surgical resection or local ablation.
MLA
Vogel, A., et al. “1017TiP KEYNOTE-937 Trial in Progress: Adjuvant Pembrolizumab in Patients with Hepatocellular Carcinoma (HCC) and Complete Radiologic Response after Surgical Resection or Local Ablation.” Annals of Oncology, vol. 31, Sept. 2020, p. S703. EBSCOhost, https://doi.org/10.1016/j.annonc.2020.08.1133.
APA
Vogel, A., Zhu, A. X., Cheng, A.-L., Yau, T., Zhou, J., Kim, E., Malhotra, U., Siegel, A. B., & Kudo, M. (2020). 1017TiP KEYNOTE-937 trial in progress: adjuvant pembrolizumab in patients with hepatocellular carcinoma (HCC) and complete radiologic response after surgical resection or local ablation. Annals of Oncology, 31, S703. https://doi.org/10.1016/j.annonc.2020.08.1133
Chicago
Vogel, A., A.X. Zhu, A-L. Cheng, T. Yau, J. Zhou, E. Kim, U. Malhotra, A.B. Siegel, and M. Kudo. 2020. “1017TiP KEYNOTE-937 Trial in Progress: Adjuvant Pembrolizumab in Patients with Hepatocellular Carcinoma (HCC) and Complete Radiologic Response after Surgical Resection or Local Ablation.” Annals of Oncology 31 (September): S703. doi:10.1016/j.annonc.2020.08.1133.